8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 16, 2003

MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction of
incorporation) 1-9114
(Commission File
Number) 25-1211621
(I.R.S. Employer
Identification No.)

1500 Corporate Drive
Suite 400
Canonsburg, PA 15317
(Address of principal executive offices)

(724) 514-1800
(Registrant’s telephone number, including area code)

Item 5. Other Events

     On September 16, 2003, Mylan Laboratories Inc., a Pennsylvania corporation (the “Company”), issued a press release announcing that its Board of Directors approved a three-for-two stock split of the Company’s Common Stock. A copy of such press release is attached hereto as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

(c)  Exhibits.

Exhibit No.	Description
99.1	Press release of the registrant, dated September 16, 2003.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MYLAN LABORATORIES INC.
Date:	September 16, 2003	By: /s/ Edward J. Borkowski Edward J. Borkowski Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of the registrant, dated September 16, 2003.

EX-99.1 3 j0311201exv99w1.htm EXHIBIT 99.1

EXHIBIT 99.1

NEWS RELEASE	FOR IMMEDIATE RELEASE
FOR: Mylan Laboratories Inc.           1500 Corporate Dr., Suite 400           Canonsburg, PA 15317	For Further Information CONTACT: Kris King                       (724) 514-1800

Pittsburgh, PA –September 16, 2003 – Mylan Laboratories Inc. (NYSE: MYL) announced today that the Board of Directors has approved a three-for-two stock split of the Company’s common shares. The split will be effected by issuing one additional share of common stock for every two shares of common stock held. The additional shares will be distributed on October 8, 2003, to holders of record at the close of business on September 30, 2003. Fractional share amounts resulting from the split will be paid to shareholders in cash. As disclosed earlier this week, Mylan’s quarterly cash dividend of $0.0333 per share will likewise be paid to holders of record on September 30, 2003 on the basis of pre-split holdings.

Vice Chairman and CEO, Robert J. Coury stated, “This is the eleventh stock split in Mylan’s history. Our decision further demonstrates the Board of Directors’ and management’s confidence in the strong fundamentals of our business and the long-term opportunities that lie ahead.”

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute “forward-looking statements”, including with regard to the stock split and the Company’s fundamentals and long-term opportunities. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: adverse market or industry conditions; the impact of competition; the results of pending or future legal proceedings and other contingencies; changes in legislation and regulations affecting Mylan’s products or its industry; and the other risks detailed in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

-----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

Exhibit 99.1